Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528867 | 0.92 | KDM4E (0.47) | KDM4ESMN1; SMN2NPC1HPGDRAB9A | |
| SCHEMBL4523204 | 0.90 | KDM4E (0.49) | KDM4EKMT2AGAANPSR1 | |
| SCHEMBL4530359 | 0.90 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2NPC1HPGD | |
| SCHEMBL5648903 | 0.87 | KDM4E (0.53) | KDM4EALDH1A1SMN1; SMN2NPC1HPGD | |
| SCHEMBL8240403 | 0.84 | KDM4E (0.48) | KDM4EALDH1A1HPGDTP53MAPT | |
| SCHEMBL13605638 | 0.77 | TP53 (0.50) | KDM4EALDH1A1TP53MAPTLMNA | |
| SCHEMBL13605637 | 0.77 | KDM4E (0.52) | KDM4EALDH1A1HPGD | |
| SCHEMBL5516014 | 0.76 | LIMK1 (0.66) | KDM4EALDH1A1NPC1HPGDRAB9A | |
| SCHEMBL8239980 | 0.74 | IKBKB (0.43) | KDM4EALDH1A1 | |
| SCHEMBL4518884 | 0.73 | MAPT (0.43) | KDM4EALDH1A1SMN1; SMN2HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2009-12-31 | — | — | US | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2009-12-31 | — | — | US | disclosed |
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2009-12-31 | — | — | US | disclosed |
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRIK5 | KDM4E 3491/4885ALDH1A1 3056/4885SMN1; SMN2 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.